Mycobacterial Virulence: Impact on Immunogenicity and Vaccine Research

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2020 Feb 13

PMID 32047597

Citations 12

Authors

Vera M Kroesen

Jan Madacki

Wafa Frigui

Fadel Sayes

Roland Brosch

Affiliations

Soon will be listed here.

Abstract

The borderline between virulence and efficacy in live attenuated vaccine strains is often blurred and this is also the case for the Bacillus Calmette-Guérin (BCG), the only currently licensed anti-tuberculosis vaccine used on a large, global scale, which was obtained almost 100 years ago. While BCG is more than 99% identical at the genome level to , the causative pathogen of human tuberculosis, some important differences in virulence factors cause naturally irreversible attenuation and safety of this vaccine in the immunocompetent host. Some of these virulence factors are involved in persistence capacities of the vaccine strains and also represent strong immunogens, responsible for inducing different host signaling pathways, which have to be taken into consideration for the development of revised and new vaccine strains. Here we discuss a number of selected mycobacterial features in relation to their biological functions and potential impact on virulence and vaccine efficacy.

Citing Articles

Mycobacterium tuberculosis: The Mechanism of Pathogenicity, Immune Responses, and Diagnostic Challenges.

Mohammadnabi N, Shamseddin J, Emadi M, Bodaghi A, Varseh M, Shariati A J Clin Lab Anal. 2024; 38(23):e25122.

PMID: 39593272 PMC: 11632860. DOI: 10.1002/jcla.25122.

The role of ESAT-6 in tuberculosis immunopathology.

Passos B, Araujo-Pereira M, Vinhaes C, Amaral E, Andrade B Front Immunol. 2024; 15:1383098.

PMID: 38633252 PMC: 11021698. DOI: 10.3389/fimmu.2024.1383098.

Identification of Differential Circular RNA Expression Profiles and Functional Networks in Human Macrophages Induced by Virulent and Avirulent Strains.

Zhu Y, Kong D, Wang Z, Li T, Tang T, Peng Y Int J Mol Sci. 2023; 24(24).

PMID: 38139387 PMC: 10744075. DOI: 10.3390/ijms242417561.

EspB and HtpG interact with the type III-A CRISPR/Cas system of .

Shi M, Zhang H, Fleming J, Wei W, Chen H, Dai X Front Mol Biosci. 2023; 10:1261613.

PMID: 38090672 PMC: 10715591. DOI: 10.3389/fmolb.2023.1261613.

Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.

Blazevic A, Edwards R, Xia M, Eickhoff C, Hamzabegovic F, Meza K J Infect Dis. 2023; 229(5):1498-1508.

PMID: 38019956 PMC: 11095547. DOI: 10.1093/infdis/jiad441.

References

Bloch H, NOLL H . Studies on the virulence of Tubercle bacilli; the effect of cord factor on murine tuberculosis. Br J Exp Pathol. 1955; 36(1):8-17. PMC: 2082506. View

Pym A, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A . Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med. 2003; 9(5):533-9. DOI: 10.1038/nm859. View

Ndiaye B, Thienemann F, Ota M, Landry B, Camara M, Dieye S . Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2015; 3(3):190-200. PMC: 4648060. DOI: 10.1016/S2213-2600(15)00037-5. View

Cooper A . Cell-mediated immune responses in tuberculosis. Annu Rev Immunol. 2009; 27:393-422. PMC: 4298253. DOI: 10.1146/annurev.immunol.021908.132703. View

Verver S, Warren R, Beyers N, Richardson M, van der Spuy G, Borgdorff M . Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. 2005; 171(12):1430-5. DOI: 10.1164/rccm.200409-1200OC. View

Unnikrishnan M, Constantinidou C, Palmer T, Pallen M . The Enigmatic Esx Proteins: Looking Beyond Mycobacteria. Trends Microbiol. 2016; 25(3):192-204. DOI: 10.1016/j.tim.2016.11.004. View

Gengenbacher M, Nieuwenhuizen N, Vogelzang A, Liu H, Kaiser P, Schuerer S . Deletion of nuoG from the Vaccine Candidate Mycobacterium bovis BCG ΔureC::hly Improves Protection against Tuberculosis. mBio. 2016; 7(3). PMC: 4895111. DOI: 10.1128/mBio.00679-16. View

Sula L, RADKOVSKY I . Protective effects of M. microti vaccine against tuberculosis. J Hyg Epidemiol Microbiol Immunol. 1976; 20(1):1-6. View

Lou Y, Rybniker J, Sala C, Cole S . EspC forms a filamentous structure in the cell envelope of Mycobacterium tuberculosis and impacts ESX-1 secretion. Mol Microbiol. 2016; 103(1):26-38. DOI: 10.1111/mmi.13575. View

10.

Sassetti C, Boyd D, Rubin E . Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol. 2003; 48(1):77-84. DOI: 10.1046/j.1365-2958.2003.03425.x. View

11.

Sapriel G, Brosch R . Shared Pathogenomic Patterns Characterize a New Phylotype, Revealing Transition toward Host-Adaptation Long before Speciation of Mycobacterium tuberculosis. Genome Biol Evol. 2019; 11(8):2420-2438. PMC: 6736058. DOI: 10.1093/gbe/evz162. View

12.

Kupz A, Zedler U, Staber M, Perdomo C, Dorhoi A, Brosch R . ESAT-6-dependent cytosolic pattern recognition drives noncognate tuberculosis control in vivo. J Clin Invest. 2016; 126(6):2109-22. PMC: 4887189. DOI: 10.1172/JCI84978. View

13.

Cambier C, OLeary S, OSullivan M, Keane J, Ramakrishnan L . Phenolic Glycolipid Facilitates Mycobacterial Escape from Microbicidal Tissue-Resident Macrophages. Immunity. 2017; 47(3):552-565.e4. PMC: 5610147. DOI: 10.1016/j.immuni.2017.08.003. View

14.

Kumarasamy N, Poongulali S, Beulah F, Akite E, Ayuk L, Bollaerts A . Long-term safety and immunogenicity of the M72/AS01E candidate tuberculosis vaccine in HIV-positive and -negative Indian adults: Results from a phase II randomized controlled trial. Medicine (Baltimore). 2018; 97(45):e13120. PMC: 6250513. DOI: 10.1097/MD.0000000000013120. View

15.

Maglione P, Chan J . How B cells shape the immune response against Mycobacterium tuberculosis. Eur J Immunol. 2009; 39(3):676-86. PMC: 2760469. DOI: 10.1002/eji.200839148. View

16.

Desvignes L, Wolf A, Ernst J . Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis. J Immunol. 2012; 188(12):6205-15. PMC: 3370955. DOI: 10.4049/jimmunol.1200255. View

17.

Stinear T, Seemann T, Harrison P, Jenkin G, Davies J, Johnson P . Insights from the complete genome sequence of Mycobacterium marinum on the evolution of Mycobacterium tuberculosis. Genome Res. 2008; 18(5):729-41. PMC: 2336800. DOI: 10.1101/gr.075069.107. View

18.

Marmiesse M, Brodin P, Buchrieser C, Gutierrez C, Simoes N, Vincent V . Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex. Microbiology (Reading). 2004; 150(Pt 2):483-496. DOI: 10.1099/mic.0.26662-0. View

19.

Zhang M, Chen J, Sala C, Rybniker J, Dhar N, Cole S . EspI regulates the ESX-1 secretion system in response to ATP levels in Mycobacterium tuberculosis. Mol Microbiol. 2014; 93(5):1057-1065. PMC: 4150839. DOI: 10.1111/mmi.12718. View

20.

Frigui W, Bottai D, Majlessi L, Monot M, Josselin E, Brodin P . Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. PLoS Pathog. 2008; 4(2):e33. PMC: 2242835. DOI: 10.1371/journal.ppat.0040033. View